Providence Wealth Advisors LLC Has $1.44 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Providence Wealth Advisors LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,571 shares of the medical research company’s stock after purchasing an additional 50 shares during the period. Amgen comprises 1.1% of Providence Wealth Advisors LLC’s holdings, making the stock its 28th largest holding. Providence Wealth Advisors LLC’s holdings in Amgen were worth $1,443,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Larson Financial Group LLC grew its stake in shares of Amgen by 29.2% in the 3rd quarter. Larson Financial Group LLC now owns 1,021 shares of the medical research company’s stock valued at $329,000 after buying an additional 231 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Amgen by 21.3% in the third quarter. Fisher Asset Management LLC now owns 102,352 shares of the medical research company’s stock worth $32,979,000 after purchasing an additional 17,974 shares in the last quarter. DRW Securities LLC bought a new stake in shares of Amgen during the 3rd quarter worth about $244,000. Loomis Sayles & Co. L P grew its holdings in Amgen by 6.6% during the third quarter. Loomis Sayles & Co. L P now owns 854 shares of the medical research company’s stock valued at $275,000 after purchasing an additional 53 shares during the last quarter. Finally, Qsemble Capital Management LP acquired a new stake in shares of Amgen in the third quarter worth $230,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on AMGN shares. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Truist Financial cut their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Redburn Partners lowered their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, UBS Group reaffirmed a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $314.04.

Amgen Stock Down 0.4 %

Shares of AMGN stock opened at $305.71 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The firm’s fifty day moving average price is $299.66 and its two-hundred day moving average price is $298.46. The firm has a market capitalization of $164.23 billion, a P/E ratio of 40.49, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.11%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now directly owns 62,147 shares in the company, valued at $18,222,743.34. The trade was a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 over the last quarter. 0.69% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.